InMed Pharmaceuticals Inc (INM)vsMerck & Company Inc (MRK)
INM
InMed Pharmaceuticals Inc
$1.43
0.00%
HEALTHCARE · Cap: $7.80M
MRK
Merck & Company Inc
$149.54
-2.33%
HEALTHCARE · Cap: $335.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1346742% more annual revenue ($66.57B vs $4.94M). MRK leads profitability with a 4.8% profit margin vs -172.2%. MRK earns a higher WallStSmart Score of 34/100 (F).
INM
Avoid32
out of 100
Grade: F
MRK
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INM.
Margin of Safety
-84.6%
Fair Value
$82.62
Current Price
$149.54
$66.92 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -143.8% — below average capital efficiency
Revenue declined 26.2%
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : INM
The strongest argument for INM centers on Price/Book, Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : INM
The primary concerns for INM are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
INM profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
INM carries more volatility with a beta of 0.98 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (34/100 vs 32/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
InMed Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?